β-Blockers Not Always Indicated for PCI Patients

Share this content:
β-Blockers Not Always Indicated for PCI Patients
β-Blockers Not Always Indicated for PCI Patients

WEDNESDAY, Aug. 17, 2016 (HealthDay News) -- Clinicians might be overprescribing β-blocker medications to heart patients, according to research published in the Aug. 22 issue of JACC: Cardiovascular Interventions.

Valay Parikh, M.D., a cardiology fellow with the North Shore LIJ-Staten Island University Hospital in New York, and colleagues reviewed records for 755,215 heart patients who were treated between January 2005 and March 2013. They focused solely on patients with stable angina without prior history of myocardial infarction (MI) or systolic heart failure undergoing elective percutaneous coronary intervention (PCI). All patients were ≥65 years of age. Of these patients, 71.4 percent had been prescribed a β-blocker, and the use of β-blockers for PCI patients increased during the eight-year study period.

The team found no significant difference between PCI patients taking β-blockers and those who were not. Three years following surgery, the mortality rate was about the same for the two groups, as were the rates of MI and stroke, the researchers reported. Also, 8.0 percent of patients taking β-blockers were readmitted to the hospital due to heart failure, compared to 6.1 percent of patients not on the medication.

"The use of β-blockers in this population should be tailored based on other concomitant cardiovascular conditions and completeness of revascularization," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »